Heterologous priming-boosting with DNA and vaccinia virus expressing kinetoplastid membrane protein-11 induces potent cellular immune response and confers protection against infection with antimony resistant and sensitive strains of Leishmania (Leis (Q39450472)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Heterologous priming-boosting with DNA and vaccinia virus expressing kinetoplastid membrane protein-11 induces potent cellular immune response and confers protection against infection with antimony resistant and sensitive strains of Leishmania (Leis	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

12 September 2017

Heterologous priming-boosting with DNA and vaccinia virus expressing kinetoplastid membrane protein-11 induces potent cellular immune response and confers protection against infection with antimony resistant and sensitive strains of Leishmania (Leis (English)

1 reference

Europe PubMed Central

12 September 2017

1 reference

based on heuristic

inferred from title

membrane protein

1 reference

based on heuristic

inferred from title

object named as

vaccinia virus

1 reference

based on heuristic

inferred from title

6

object named as

Shyam Sundar

1 reference

Europe PubMed Central

12 September 2017

author name string

Rajan Guha

1

1 reference

Europe PubMed Central

12 September 2017

Shantanabha Das

2

1 reference

Europe PubMed Central

12 September 2017

June Ghosh

3

1 reference

Europe PubMed Central

12 September 2017

Kshudiram Naskar

4

1 reference

Europe PubMed Central

12 September 2017

Ashok Mandala

5

1 reference

Europe PubMed Central

12 September 2017

Jean Claude Dujardin

7

1 reference

Europe PubMed Central

12 September 2017

Syamal Roy

8

1 reference

Europe PubMed Central

12 September 2017

language of work or name

0 references

publication date

26 February 2013

1 reference

Europe PubMed Central

12 September 2017

number of pages

11

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

12 September 2017

31

1 reference

Europe PubMed Central

12 September 2017

15

1 reference

Europe PubMed Central

12 September 2017

1905-1915

1 reference

Europe PubMed Central

12 September 2017

Drug resistance in leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.025

7 January 2021

Genetic markers for SSG resistance in Leishmania donovani and SSG treatment failure in visceral leishmaniasis patients of the Indian subcontinent

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.025

7 January 2021

Combination therapy for visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.025

7 January 2021

Vaccines for the leishmaniases: proposals for a research agenda

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.025

7 January 2021

DNA vaccines: immunology, application, and optimization*

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.025

7 January 2021

Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.025

7 January 2021

Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.025

7 January 2021

Immunization with the cysteine proteinase Ldccys1 gene from Leishmania (Leishmania) chagasi and the recombinant Ldccys1 protein elicits protective immune responses in a murine model of visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.025

7 January 2021

Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.025

7 January 2021

Vaccination with recombinant Parasite Surface Antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.025

7 January 2021

Immunization strategies against visceral leishmaniosis with the nucleosomal histones of Leishmania infantum encoded in DNA vaccine or pulsed in dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.025

7 January 2021

Cellular and humoral responses induced by Leishmania histone H2B and its divergent and conserved parts in cutaneous and visceral leishmaniasis patients, respectively

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.025

7 January 2021

Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generati

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.025

7 January 2021

KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.025

7 January 2021

Therapeutic vaccination with recombinant adenovirus reduces splenic parasite burden in experimental visceral leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.025

7 January 2021

HLA class I-restricted T cell epitopes of the kinetoplastid membrane protein-11 presented by Leishmania donovani-infected human macrophages

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.025

7 January 2021

Heterologous priming-boosting with DNA and modified vaccinia virus Ankara expressing tryparedoxin peroxidase promotes long-term memory against Leishmania major in susceptible BALB/c Mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.025

7 January 2021

Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.025

7 January 2021

Heterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.025

7 January 2021

The prime-boost strategy: exciting prospects for improved vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.025

7 January 2021

Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.025

7 January 2021

A heterologous prime-boost regime using DNA and recombinant vaccinia virus expressing the Leishmania infantum P36/LACK antigen protects BALB/c mice from cutaneous leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.025

7 January 2021

Immunogenicity and efficacy of single antigen Gp63, polytope and polytopeHSP70 DNA vaccines against visceral Leishmaniasis in experimental mouse model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.025

7 January 2021

Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.025

7 January 2021

IL-10 from regulatory T cells determines vaccine efficacy in murine Leishmania major infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.025

7 January 2021

Characterisation of antimony-resistant Leishmania donovani isolates: biochemical and biophysical studies and interaction with host cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.025

7 January 2021

Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.025

7 January 2021

A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.025

7 January 2021

Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.025

7 January 2021

Enhancement of immunodeficiency virus-specific immune responses in DNA-immunized rhesus macaques.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.025

7 January 2021

Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.025

7 January 2021

Induction of CD8+ T cells using heterologous prime-boost immunisation strategies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.025

7 January 2021

T-cell quality in memory and protection: implications for vaccine design

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.025

7 January 2021

Vector transmission of leishmania abrogates vaccine-induced protective immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.025

7 January 2021

Intradermal infection model for pathogenesis and vaccine studies of murine visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.025

7 January 2021

Leishmania donovani affects antigen presentation of macrophage by disrupting lipid rafts

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.025

7 January 2021

Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.025

7 January 2021

High quality long-term CD4+ and CD8+ effector memory populations stimulated by DNA-LACK/MVA-LACK regimen in Leishmania major BALB/c model of infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.025

7 January 2021

A DNA prime-live vaccine boost strategy in mice can augment IFN-gamma responses to mycobacterial antigens but does not increase the protective efficacy of two attenuated strains of Mycobacterium bovis against bovine tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.025

7 January 2021

Biological functions of tumor necrosis factor cytokines and their receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.025

7 January 2021

Tumor necrosis factor-alpha in combination with interferon-gamma, but not with interleukin 4 activates murine macrophages for elimination of Leishmania major amastigotes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.025

7 January 2021

Multifunctional CD4⁺ T cells in patients with American cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.025

7 January 2021

B7-H1 blockade increases survival of dysfunctional CD8(+) T cells and confers protection against Leishmania donovani infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.025

7 January 2021

Skewing of cytokine profiles towards T helper cell type 2 response in visceral leishmaniasis patients unresponsive to sodium antimony gluconate

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.025

7 January 2021

Identifiers

10.1016/J.VACCINE.2013.02.025

1 reference

Europe PubMed Central

12 September 2017

release_ftg7suwrrvfjnnwpccvxio7uvm

1 reference

https://api.fatcat.wiki/v0/release/ftg7suwrrvfjnnwpccvxio7uvm

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

12 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39450472&oldid=1837050709"